Fortitude Biomedicines

About Fortitude Biomedicines

Fortitude Biomedicines is pioneering the next generation of antibody-based biotherapeutics to transform the treatment of autoimmune diseases and cancer. Their mission is to deliver medicines that minimize off-target effects, enhance efficacy, and improve patient outcomes through precision cell targeting and innovative biologics.

Products & Services

GLUE-DAC™ Platform:A proprietary platform for building antibody-drug conjugates (ADCs) using molecular glue degraders as therapeutic payloads. It enables precise removal of disease-causing proteins, offering superior potency, improved safety, potential to overcome resistance, and applicability beyond cancer to autoimmune diseases.

Specialties

Precision Cell Targeting Antibody-Drug Conjugates (ADCs) Innovative Biologics Molecular Glue Degraders Autoimmune Disease Treatment Cancer Treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed T: - FT: Seed	A: 13000000 MR: - FA: $13 million FAN: 13000000	D: 2026-01-26 FD: 2026-01-26	5 investors

Seed Latest

2026-01-26

$13.0M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

John Doe

J

Jesse Chen

President and CEO

S

Stephen Monks, Ph.D.

Acting Chief Development Officer

K

Keith Dewedoff

Acting CFO

J

Jan Theunissen

Vice President, Discovery

W

Wendi Ni

Director, Operations and Corporate Development

View 7 more team members with Pro

Unlock Full Team Directory

Recent News